Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
OPHT's Cash to Debt is ranked higher than
75% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: 46.43 vs. OPHT: No Debt )
Ranked among companies with meaningful Cash to Debt only.
OPHT' s Cash to Debt Range Over the Past 10 Years
Min: 0.4  Med: No Debt Max: No Debt
Current: No Debt
Equity to Asset -0.10
OPHT's Equity to Asset is ranked lower than
94% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. OPHT: -0.10 )
Ranked among companies with meaningful Equity to Asset only.
OPHT' s Equity to Asset Range Over the Past 10 Years
Min: -0.1  Med: 0.18 Max: 0.36
Current: -0.1
-0.1
0.36
Interest Coverage No Debt
OPHT's Interest Coverage is ranked higher than
66% of the 458 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. OPHT: No Debt )
Ranked among companies with meaningful Interest Coverage only.
OPHT' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
F-Score: 3
Z-Score: -0.67
M-Score: -3.87
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -336.93
OPHT's Operating margin (%) is ranked lower than
65% of the 749 Companies
in the Global Biotechnology industry.

( Industry Median: -78.20 vs. OPHT: -336.93 )
Ranked among companies with meaningful Operating margin (%) only.
OPHT' s Operating margin (%) Range Over the Past 10 Years
Min: -336.93  Med: -217.49 Max: -195.14
Current: -336.93
-336.93
-195.14
Net-margin (%) -323.19
OPHT's Net-margin (%) is ranked lower than
65% of the 749 Companies
in the Global Biotechnology industry.

( Industry Median: -75.28 vs. OPHT: -323.19 )
Ranked among companies with meaningful Net-margin (%) only.
OPHT' s Net-margin (%) Range Over the Past 10 Years
Min: -323.19  Med: -244.14 Max: -205.26
Current: -323.19
-323.19
-205.26
ROE (%) -527.85
OPHT's ROE (%) is ranked lower than
97% of the 878 Companies
in the Global Biotechnology industry.

( Industry Median: -33.45 vs. OPHT: -527.85 )
Ranked among companies with meaningful ROE (%) only.
OPHT' s ROE (%) Range Over the Past 10 Years
Min: -527.85  Med: -112.18 Max: -78.3
Current: -527.85
-527.85
-78.3
ROA (%) -40.40
OPHT's ROA (%) is ranked lower than
59% of the 971 Companies
in the Global Biotechnology industry.

( Industry Median: -29.51 vs. OPHT: -40.40 )
Ranked among companies with meaningful ROA (%) only.
OPHT' s ROA (%) Range Over the Past 10 Years
Min: -241.11  Med: -45.96 Max: -23.27
Current: -40.4
-241.11
-23.27
ROC (Joel Greenblatt) (%) -2283.80
OPHT's ROC (Joel Greenblatt) (%) is ranked lower than
71% of the 931 Companies
in the Global Biotechnology industry.

( Industry Median: -372.06 vs. OPHT: -2283.80 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
OPHT' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -26895.89  Med: -16410.03 Max: -2283.8
Current: -2283.8
-26895.89
-2283.8
» OPHT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

OPHT Guru Trades in Q4 2015

Samuel Isaly 331,000 sh (unchged)
Jim Simons 301,415 sh (-20.15%)
Pioneer Investments 83,168 sh (-34.96%)
» More
Q1 2016

OPHT Guru Trades in Q1 2016

Steven Cohen 414,400 sh (New)
Paul Tudor Jones 11,296 sh (New)
Jim Simons 362,500 sh (+20.27%)
Samuel Isaly 331,000 sh (unchged)
Pioneer Investments 64,092 sh (-22.94%)
» More
Q2 2016

OPHT Guru Trades in Q2 2016

Samuel Isaly 331,000 sh (unchged)
Jim Simons Sold Out
Steven Cohen Sold Out
Pioneer Investments 63,987 sh (-0.16%)
Paul Tudor Jones 10,501 sh (-7.04%)
» More
Q3 2016

OPHT Guru Trades in Q3 2016

Steven Cohen 786,300 sh (New)
Pioneer Investments 86,992 sh (+35.95%)
Paul Tudor Jones 7,094 sh (-32.44%)
Samuel Isaly 284,600 sh (-14.02%)
» More
» Details

Insider Trades

Latest Guru Trades with OPHT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NYSE:AXON, NAS:ARRY, NAS:XLRN, OTCPK:GENSF, NAS:CLVS, NAS:AAAP, NAS:FGEN, NAS:ALDR, NAS:FOLD, NAS:TBPH, NAS:CHRS, NYSE:EBS, OTCPK:MPSYY, NAS:DERM, OTCPK:SXMDF, NYSE:CBM, NAS:AMAG, NAS:RGEN, NAS:AVXS, NAS:INVA » details
Traded in other countries:O2T.Germany,
Ophthotech Corp is a biopharmaceutical company. The Company is engaged in the development of novel therapeutics to treat diseases of the back of the eye, developing therapeutics for age-related macular degeneration.

Ratios

vs
industry
vs
history
P/S 25.87
OPHT's P/S is ranked lower than
67% of the 695 Companies
in the Global Biotechnology industry.

( Industry Median: 10.41 vs. OPHT: 25.87 )
Ranked among companies with meaningful P/S only.
OPHT' s P/S Range Over the Past 10 Years
Min: 18.75  Med: 35.76 Max: 70.15
Current: 25.87
18.75
70.15
Current Ratio 6.07
OPHT's Current Ratio is ranked higher than
61% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.22 vs. OPHT: 6.07 )
Ranked among companies with meaningful Current Ratio only.
OPHT' s Current Ratio Range Over the Past 10 Years
Min: 0.34  Med: 16.13 Max: 40.94
Current: 6.07
0.34
40.94
Quick Ratio 6.07
OPHT's Quick Ratio is ranked higher than
63% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.94 vs. OPHT: 6.07 )
Ranked among companies with meaningful Quick Ratio only.
OPHT' s Quick Ratio Range Over the Past 10 Years
Min: 0.34  Med: 16.13 Max: 40.94
Current: 6.07
0.34
40.94
Days Sales Outstanding 175.88
OPHT's Days Sales Outstanding is ranked lower than
87% of the 601 Companies
in the Global Biotechnology industry.

( Industry Median: 61.72 vs. OPHT: 175.88 )
Ranked among companies with meaningful Days Sales Outstanding only.
OPHT' s Days Sales Outstanding Range Over the Past 10 Years
Min: 8.49  Med: 31.92 Max: 175.88
Current: 175.88
8.49
175.88

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.68
OPHT's Price/Median PS Value is ranked higher than
70% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: 0.93 vs. OPHT: 0.68 )
Ranked among companies with meaningful Price/Median PS Value only.
OPHT' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.55  Med: 0.96 Max: 1.62
Current: 0.68
0.55
1.62
Earnings Yield (Greenblatt) (%) -14.48
OPHT's Earnings Yield (Greenblatt) (%) is ranked lower than
66% of the 942 Companies
in the Global Biotechnology industry.

( Industry Median: -8.50 vs. OPHT: -14.48 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
OPHT' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -20.01  Med: 0 Max: 0
Current: -14.48
-20.01
0

More Statistics

Revenue (TTM) (Mil) $50.37
EPS (TTM) $ -4.62
Beta2.29
Short Percentage of Float16.33%
52-Week Range $29.85 - 80.00
Shares Outstanding (Mil)35.70

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 82 170 519
EPS ($) -4.55 -2.15 3.25
EPS w/o NRI ($) -4.55 -2.15 3.25
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for OPHT

Headlines

Articles On GuruFocus.com
Largest Insiders' Trades of the Week May 27 2016 
Can These Three BioTech Companies Make It Big? Feb 20 2015 
Weekly 3-Year Low Highlight: VIV, CNHI, WTW, OPHT Nov 17 2013 
Insiders Are Buying Ophthotech Oct 08 2013 

More From Other Websites
Ophthotech Corp. breached its 50 day moving average in a Bearish Manner : OPHT-US : December 7, 2016 Dec 07 2016
ETFs with exposure to Ophthotech Corp. : December 1, 2016 Dec 01 2016
Not An Options Expert? You Can Still Use Options Market For Stock Trading Ideas Dec 01 2016
Why Is The Smart Money So Bullish On Ophthotech Corp (OPHT)? Nov 24 2016
ETFs with exposure to Ophthotech Corp. : November 18, 2016 Nov 18 2016
OPHTHOTECH CORP. Financials Nov 17 2016
Ophthotech Corp. :OPHT-US: Earnings Analysis: Q3, 2016 By the Numbers : November 17, 2016 Nov 17 2016
Ophthotech (OPHT) Q3 Loss Wider than Expected, Sales Fall Nov 09 2016
Edited Transcript of OPHT earnings conference call or presentation 8-Nov-16 1:00pm GMT Nov 08 2016
OPHTHOTECH CORP. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Nov 08 2016
Ophthotech reports 3Q loss Nov 08 2016
Ophthotech reports 3Q loss Nov 08 2016
Ophthotech Reports Third Quarter 2016 Financial and Operating Results Nov 08 2016
Ophthotech Reports Third Quarter 2016 Financial and Operating Results Nov 08 2016
Q3 2016 Ophthotech Corp Earnings Release - Before Market Open Nov 08 2016
Drug Stock Earnings to Watch on Nov 8: JAZZ, VRX, TBPH, OPHT Nov 07 2016
OPHTHOTECH CORP. Files SEC form 8-K, Entry into a Material Definitive Agreement Nov 04 2016
What Is A Lottery Ticket Trade? Nov 02 2016
Ophthotech Rises on Positive Mid-Stage Results Oct 31 2016
Ophthotech Announces the Publication of Fovista® in Combination with Lucentis® Phase 2b Study... Oct 31 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)